文献速递免疫规划卫生政策与健康促进

澳大利亚维多利亚州接种Vaxzevria ChadOx1-S(阿斯利康)疫苗后免疫性血小板减少症

Immune thrombocytopenia following immunisation with Vaxzevria ChadOx1-S (AstraZeneca) vaccine, Victoria, Australia.
PubMed 文献 · Vaccine · 2021-10-30

该研究对2021年澳大利亚COVID-19疫苗接种推广最初六个月期间,向维多利亚州疫苗安全服务机构SAEFVIC报告的18岁及以上、接种COVID-19疫苗后出现血小板减少且无血栓证据的个体进行回顾性病例系列分析。共确认21例免疫性血小板减少症(ITP)病例,其中阿斯利康疫苗17例、辉瑞-BioNTech疫苗4例;阿斯利康疫苗观察发生率为每百万剂8例,是预期背景发生率每百万4.1例的两倍,辉瑞-BioNTech疫苗观察发生率与预期背景发生率一致。结论认为阿斯利康疫苗接种后ITP发生率显著高于预期。

要点

  • 阿斯利康疫苗接种后ITP观察发生率为每百万剂8例,是预期背景发生率每百万4.1例的两倍。
  • 辉瑞-BioNTech疫苗接种后ITP观察发生率与预期背景发生率一致。
  • 阿斯利康疫苗接种后ITP中位发病时间为10天(范围1-78天),中位血小板最低值为5×10^9/L(范围0-67×10^9/L)。

核心结论

  • 阿斯利康疫苗接种后观察到ITP发生率显著高于预期,ITP是阿斯利康疫苗接种后观察到的第二种血液学不良事件,与血栓伴血小板减少综合征(TTS)不同。

研究设计与样本

  • 回顾性病例系列,纳入2021年澳大利亚COVID-19疫苗接种推广最初六个月期间向维多利亚州疫苗安全服务机构SAEFVIC报告的18岁及以上、接种COVID-19疫苗后出现血小板减少且无血栓证据的个体。

主要发现

  • 共确认21例确诊或很可能ITP病例,其中接种阿斯利康疫苗17例、接种辉瑞-BioNTech疫苗4例。
  • 阿斯利康疫苗观察发生率为每百万剂8例,是预期背景发生率每百万4.1例的两倍;辉瑞-BioNTech疫苗观察发生率与预期背景发生率一致。
  • 阿斯利康疫苗接种后ITP中位发病时间为10天(范围1-78天),中位血小板最低值为5×10^9/L(范围0-67×10^9/L)。
  • 18例(86%)因出血等症状到医院就诊或住院治疗,多数病例(11例)需要至少两种治疗方式干预。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Emerging evidence suggest a possible association between immune thrombocytopenia (ITP) and some formulations of COVID-19 vaccine. We conducted a retrospective case series of ITP following vaccination with Vaxzevria ChadOx1-S (AstraZeneca) and mRNA Comirnaty BNT162b2 COVID-19 (Pfizer-BioNTech) vaccines and compare the incidence to expected background rates for Victoria during the first six months of the Australian COVID-19 vaccination roll-out in 2021. Cases were identified by reports to the Victorian state vaccine safety service, SAEFVIC, of individuals aged 18 years or older presenting with thrombocytopenia following COVID-19 vaccination without evidence of thrombosis. Twenty-one confirmed or probable cases of ITP were identified following receipt of AstraZeneca (n = 17) or Pfizer-BioNTech (n = 4) vaccines. This translates to an observed incidence of 8 per million doses for AstraZeneca vaccine, twice the expected background rate of 4.1 per million. The observed rate for Pfizer-BioNTech was consistent with the expected background rate. The median time to onset for the cases post AstraZeneca vaccination was 10 days (range 1-78) and median platelet nadir 5 × 109/L (range 0-67 × 109/L). Hospital presentations or admissions for management of symptoms such as bleeding occurred in 18 (86%) of the cases. The majority of cases (n = 11) required intervention with at least 2 therapy modalities. In conclusion, we observed a substantially higher than expected rate of ITP following AstraZeneca vaccination. ITP is the second haematological adverse event, distinct from that of thrombosis with thrombocytopenia syndrome (TTS), observed following AstraZeneca vaccination.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Gordon SF, Clothier HJ, Morgan H, et al. Immune thrombocytopenia following immunisation with Vaxzevria ChadOx1-S (AstraZeneca) vaccine, Victoria, Australia. Vaccine. 2021. PMID: 34756770. doi:10.1016/j.vaccine.2021.10.030

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。